Each drug is made up of two components that are API and excipients, having curative activity. APIs are often known as bulk pharmaceuticals and most of all APIs are in powder form. Active Pharmaceutical Ingredients (APIs) are active substances in a drug intended to achieve pharmacological activity which is having a direct effect on disease treatment. APIs are synthesized based on chemical synthesis, fermentation, biotechnological methods or enhanced from the natural source.
Pharmaceutical excipients are inactive substances in the drug which help in modulating the solubility, bioavailability, and stability of active substances for formulating final drug dosage forms. The excipients form the major part of any medicinal product and the proportion of it, when compared to Active Pharmaceutical Ingredient (API), exceeds two to three folds in any pharmaceutical preparations. Hence, various characteristics such as functionality, regulatory status, sources, cost, consistency, bioavailability, physicochemical properties, stability, pharmacokinetic parameters, etc. play a major role in determining the suitability of a substance as an excipient.
Cell lines are major tools used in research for studying the normal physiology and biochemistry of cells, the effects of drugs and toxic compounds on the cells, drug screening and development and large scale manufacturing of biological compounds. Cell culture is the process by which cells are grown under controlled conditions derived from microbial or animal cells. Cell lines are subculture of primary culture also known as sub-clone. Cell lines derived from primary cultures have a limited life span, after subsequent cultures, cells with the highest growth capacity dominate which are selected for further cell development. Primary cells are cells that are cultured directly from a subject and have a limited lifespan. An immortalized cell line can proliferate indefinitely either through random mutation or deliberate modification which are useful especially for production of therapeutics.
Biologics are the therapeutic entities composed of sugars, proteins, or nucleic acids and made from natural sources such as human, animal or microorganisms. Biologics also include live attenuated microorganisms (vaccines), allergenic extracts (allergy shots), human cells and tissues (for transplantation), cell and gene therapeutics. Similar to the conventional therapeutics, these drugs help in treating several diseases but are highly specific and more efficient in their disease healing mechanisms. The biologic entities like monoclonal antibodies and recombinant proteins target specific areas during their molecular mechanism of disease curing.
This pipeline analysis gives a comprehensive insights on the various emerging isotope based candidates being developed for the both diagnosis as well as treatment of various cancers and non-cancer indications.
The factors, such as, the increase in demand for imaging agent-assisted diagnostic procedures for better visualization due to increase in cardiovascular diseases and cancer, production of radiopharmaceuticals from cyclotrons, increasing access to diagnostic imaging in the emerging markets, increase in the aging population suffering from chronic disease, and usage of hybrid imaging technologies are driving the market growth.
Factors like high cost of drug delivery technology integrated products, concerns about the adverse effects associated with drug delivery systems, the inconsistent and evolving global drug delivery systems regulatory landscape, emergence of several therapeutic medical devices and advanced drug delivery devices and inefficiency of toxicity testing and evaluation studies in characterizing the novel drug delivery formulations are hampering the market growth.
therapeutics, patent expiration of small molecules, advanced technologies in API and FDF manufacturing, increasing deals and investments, increased demand for generic injectable, increasing incidence and prevalence of chronic diseases, and increase in geriatric population are some of the factors driving the market growth.
IQ4I Research & Consultancy published a new report on - Drug Discovery Outsourcing (DDO) Global Market - Forecast To 2030 analyzes and studies the major competition, market drivers & Opportunities, Restraints & Threats in North America, Europe, Asia-Pacific and Rest of the World.